The importance of tumor vascular behavior in clinical application is that the delivery of drugs and oxygen relied on the vascular function and morphology can determine the therapy response. To assess the vasculatures within tumors with the high spatial resolution and sensitivity, high-frequency ultrasound power Doppler imaging with a center frequency of 25 MHz was adopted. In power Doppler imaging, the vascular function was quantified based on the color-weighted flow area (CWFA) and color pixel density (CPD), which reflect the perfusion and the fraction of perfused vascular density within the tumor, respectively. Besides, the branching index (BI), defined as the perimeter of blood vessels divided by their area, was also proposed to reveal the morphology of the tumor vasculatures by describing the degree of branching per unit length of blood vessels.
The first part of this dissertation is to longitudinally investigate the difference characteristics between angiogenesis and vsculogenesis pathways in primary and recurrent tumors, as described in Chapter 2. Murine tumors were transplanted in non-irradiated and pre-irradiated tissues to imitate the primary and recurrent tumor models, respectively. During tumor progression of 11 days, the CWFA and CPD increased in primary tumors but did not change significantly in recurrent tumors. The recurrent tumors showed less vascular function than in the primary tumors. These results were verified by immunohistochemistry analysis. Besides, the recurrent tumors exhibited more dilated and continuous vasculatures than the primary tumors, which reflect the BI value should theoretically be lower for recurrent tumors than for primary tumors. Nevertheless, due to the vasculature distributions being chaotic and malformed throughout the tumors, the actual morphological patterns of vasculatures in the whole tumors was obtained by three-dimensional power Doppler imaging.
Second, tumor heterogeneity is another major obstacle to therapy, and thus, not only longitudinally but also spatially assessing of tumor vascular behavior is necessary. In Chapter 3, tumor perfusion and vascular density within the primary tumors assessed by power Doppler imaging and immunohistochemical analysis were spatially and longitudinally investigated, respectively. The parameter of  value was defined as the rate at which vascular signals increase with the fractional sizes of the peripheral area within the tumor that can objectively quantify the spatial features of the tumor vasculature. To demonstrate the potential of the  value, the primary tumors were adopted in this dissertation. During primary tumor progression, the estimated tumor perfusion by power Doppler imaging and vascular density by immunohistochemical analysis exhibited good temporal correlations, but they did not present good spatial correlations. The  value calculated from power Doppler images decreased, which indicated tumor perfusion changed from homogeneous to heterogeneous. However, there were no significant differences in the immunohistochemical images, which reflected the vascular density still maintained uniformly homogeneous distribution.
In clinical, since tumors exhibit heterogeneity, how to achieve the maximal therapeutic gain in tumor suppression is an important issue. Exploring the differences in features of tumor vascular patterns between two tumor models is helpful for developing anti-angiogenic and anti-vasculogenic drugs. Furthermore, both longitudinal monitoring the change in tumor vascular behavior and spatially evaluating the different weighting of tumor vasculatures within the tumor central and peripheral regions are helpful for providing the complete tumor physiology information and adjusting appropriate dose in therapy.

The importance of tumor vascular behavior in clinical application is that the delivery of drugs and oxygen relied on the vascular function and morphology can determine the therapy response. To assess the vasculatures within tumors with the high spatial resolution and sensitivity, high-frequency ultrasound power Doppler imaging with a center frequency of 25 MHz was adopted. In power Doppler imaging, the vascular function was quantified based on the color-weighted flow area (CWFA) and color pixel density (CPD), which reflect the perfusion and the fraction of perfused vascular density within the tumor, respectively. Besides, the branching index (BI), defined as the perimeter of blood vessels divided by their area, was also proposed to reveal the morphology of the tumor vasculatures by describing the degree of branching per unit length of blood vessels.
The first part of this dissertation is to longitudinally investigate the difference characteristics between angiogenesis and vsculogenesis pathways in primary and recurrent tumors, as described in Chapter 2. Murine tumors were transplanted in non-irradiated and pre-irradiated tissues to imitate the primary and recurrent tumor models, respectively. During tumor progression of 11 days, the CWFA and CPD increased in primary tumors but did not change significantly in recurrent tumors. The recurrent tumors showed less vascular function than in the primary tumors. These results were verified by immunohistochemistry analysis. Besides, the recurrent tumors exhibited more dilated and continuous vasculatures than the primary tumors, which reflect the BI value should theoretically be lower for recurrent tumors than for primary tumors. Nevertheless, due to the vasculature distributions being chaotic and malformed throughout the tumors, the actual morphological patterns of vasculatures in the whole tumors was obtained by three-dimensional power Doppler imaging.
Second, tumor heterogeneity is another major obstacle to therapy, and thus, not only longitudinally but also spatially assessing of tumor vascular behavior is necessary. In Chapter 3, tumor perfusion and vascular density within the primary tumors assessed by power Doppler imaging and immunohistochemical analysis were spatially and longitudinally investigated, respectively. The parameter of  value was defined as the rate at which vascular signals increase with the fractional sizes of the peripheral area within the tumor that can objectively quantify the spatial features of the tumor vasculature. To demonstrate the potential of the  value, the primary tumors were adopted in this dissertation. During primary tumor progression, the estimated tumor perfusion by power Doppler imaging and vascular density by immunohistochemical analysis exhibited good temporal correlations, but they did not present good spatial correlations. The  value calculated from power Doppler images decreased, which indicated tumor perfusion changed from homogeneous to heterogeneous. However, there were no significant differences in the immunohistochemical images, which reflected the vascular density still maintained uniformly homogeneous distribution.
In clinical, since tumors exhibit heterogeneity, how to achieve the maximal therapeutic gain in tumor suppression is an important issue. Exploring the differences in features of tumor vascular patterns between two tumor models is helpful for developing anti-angiogenic and anti-vasculogenic drugs. Furthermore, both longitudinal monitoring the change in tumor vascular behavior and spatially evaluating the different weighting of tumor vasculatures within the tumor central and peripheral regions are helpful for providing the complete tumor physiology information and adjusting appropriate dose in therapy.

References
[1] G. Bergers and L. E. Benjamin, "Tumorigenesis and the angiogenic switch," Nat Rev Cancer, vol. 3, pp. 401-10, 2003.
[2] M. Cristofanilli, C. Charnsangavej, and G. N. Hortobagyi, "Angiogenesis modulation in cancer research: novel clinical approaches," Nat Rev Drug Discov, vol. 1, pp. 415-26, 2002.
[3] J. Folkman, "Angiogenesis: an organizing principle for drug discovery?," Nat Rev Drug Discov, vol. 6, pp. 273-86, 2007.
[4] D. J. Hicklin and L. M. Ellis, "Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis," J Clin Oncol, vol. 23, pp. 1011-27, 2005.
[5] J. K. Willmann, R. Paulmurugan, K. Chen, O. Gheysens, M. Rodriguez-Porcel, A. M. Lutz, et al., "US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice," Radiology, vol. 246, pp. 508-518, 2008.
[6] O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock, "Drug resistance and the solid tumor microenvironment," Journal of the National Cancer Institute, vol. 99, pp. 1441-1454, 2007.
[7] S. J. Lunt, N. Chaudary, and R. P. Hill, "The tumor microenvironment and metastatic disease," Clinical & Experimental Metastasis, vol. 26, pp. 19-34, 2009.
[8] Y. Matsumura and H. Maeda, "A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs," Cancer Res, vol. 46, pp. 6387-92, 1986.
[9] P. G. Rose, B. N. Bundy, E. B. Watkins, J. T. Thigpen, G. Deppe, M. A. Maiman, et al., "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer," N Engl J Med, vol. 340, pp. 1144-53, 1999.
[10] J. H. Tsai, S. Makonnen, M. Feldman, C. M. Sehgal, A. Maity, and W. M. F. Lee, "Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis," Cancer Biology & Therapy, vol. 4, pp. 1395-1400, 2005.
[11] M. Dizdaroglu, P. Jaruga, M. Birincioglu, and H. Rodriguez, "Free radical-induced damage to DNA: mechanisms and measurement," Free Radic Biol Med, vol. 32, pp. 1102-15, 2002.
[12] I. Tannock, "Cell kinetics and chemotherapy: a critical review," Cancer Treat Rep, vol. 62, pp. 1117-33, 1978.
[13] A. J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I. F. Tannock, "The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors," Clin Cancer Res, vol. 11, pp. 8782-8, 2005.
[14] A. I. Minchinton and I. F. Tannock, "Drug penetration in solid tumours," Nat Rev Cancer, vol. 6, pp. 583-92, 2006.
[15] J. P. Greenfield, W. S. Cobb, and D. Lyden, "Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas," Journal of Clinical Investigation, vol. 120, pp. 663-667, 2010.
[16] M. Kioi, H. Vogel, G. Schultz, R. M. Hoffman, G. R. Harsh, and J. M. Brown, "Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice," J Clin Invest, vol. 120, pp. 694-705, 2010.
[17] L. Milas, H. Ito, N. Hunter, S. Jones, and L. J. Peters, "Retardation of tumor-growth in mice caused by radiation-induced injury of tumor bed stroma - dependency on tumor type," Cancer Research, vol. 46, pp. 723-727, 1986.
[18] L. Milas, H. Hirata, N. Hunter, and L. J. Peters, "Effect of radiation-induced injury of tumor bed stroma on metastatic spread of murine sarcomas and carcinomas," Cancer Research, vol. 48, pp. 2116-2120, 1988.
[19] J. Kao, M. C. Garofalo, M. T. Milano, S. J. Chmura, J. R. Citron, and D. J. Haraf, "Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review," Cancer Treatment Reviews, vol. 29, pp. 21-30, 2003.
[20] R. H. Adams and K. Alitalo, "Molecular regulation of angiogenesis and lymphangiogenesis," Nat Rev Mol Cell Biol, vol. 8, pp. 464-78, 2007.
[21] M. J. Hendrix, E. A. Seftor, A. R. Hess, and R. E. Seftor, "Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma," Nat Rev Cancer, vol. 3, pp. 411-21, 2003.
[22] K. H. Clifton and R. Jirtle, "Mammary-carcinoma cell-population growth in preirradiated and unirradiated transplant sites - viable tumor-growth, vascularity, and tumor-bed effect," Radiology, vol. 117, pp. 459-465, 1975.
[23] E. K. Rofstad, B. Mathiesen, K. Henriksen, K. Kindem, and K. Galappathi, "The tumor bed effect: Increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products," Cancer Research, vol. 65, pp. 2387-2396, 2005.
[24] D. Zips, W. Eicheler, K. Bruchner, T. Jackisch, P. Geyer, C. Petersen, et al., "Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse," Int J Radiat Biol, vol. 77, pp. 1185-93, 2001.
[25] S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher, "Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors," Cancer Res, vol. 67, pp. 5076-82, 2007.
[26] F. H. Chen, C. S. Chiang, C. C. Wang, S. Y. Fu, C. S. Tsai, S. M. Jung, et al., "Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy," Int J Radiat Oncol Biol Phys, vol. 80, pp. 1512-21, 2011.
[27] M. Heijblom, J. M. Klaase, F. M. van den Engh, T. G. van Leeuwen, W. Steenbergen, and S. Manohar, "Imaging tumor vascularization for detection and diagnosis of breast cancer," Technol Cancer Res Treat, vol. 10, pp. 607-23, 2011.
[28] C. Kuhl, "The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice," Radiology, vol. 244, pp. 356-78, 2007.
[29] T. Barrett, M. Brechbiel, M. Bernardo, and P. L. Choyke, "MRI of tumor angiogenesis," J Magn Reson Imaging, vol. 26, pp. 235-49, 2007.
[30] K. Hida, Y. Hida, D. N. Amin, A. F. Flint, D. Panigrahy, C. C. Morton, et al., "Tumor-associated endothelial cells with cytogenetic abnormalities," Cancer Res, vol. 64, pp. 8249-55, 2004.
[31] T. Akino, K. Hida, Y. Hida, K. Tsuchiya, D. Freedman, C. Muraki, et al., "Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors," Am J Pathol, vol. 175, pp. 2657-67, 2009.
[32] C. A. Cuenod, L. Fournier, D. Balvay, and J. M. Guinebretiere, "Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment," Abdom Imaging, vol. 31, pp. 188-93, 2006.
[33] C. D. Marcus, V. Ladam-Marcus, C. Cucu, O. Bouche, L. Lucas, and C. Hoeffel, "Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives," Crit Rev Oncol Hematol, vol. 72, pp. 217-38, 2009.
[34] A. J. de Langen, V. E. van den Boogaart, J. T. Marcus, and M. Lubberink, "Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow," Oncologist, vol. 13, pp. 631-44, 2008.
[35] A. B. Hollingsworth, R. G. Stough, C. A. O'Dell, and C. E. Brekke, "Breast magnetic resonance imaging for preoperative locoregional staging," Am J Surg, vol. 196, pp. 389-97, 2008.
[36] R. H. El Khouli, M. A. Jacobs, and D. A. Bluemke, "Magnetic resonance imaging of the breast," Semin Roentgenol, vol. 43, pp. 265-81, 2008.
[37] T. Uematsu, S. Yuen, M. Kasami, and Y. Uchida, "Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer," Breast Cancer Res Treat, vol. 112, pp. 461-74, 2008.
[38] D. S. Babcock, H. Patriquin, M. LaFortune, and M. Dauzat, "Power Doppler sonography: basic principles and clinical applications in children," Pediatr Radiol, vol. 26, pp. 109-15, 1996.
[39] J. W. Xuan, M. Bygrave, H. Y. Jiang, F. Valiyeva, J. Dunmore-Buyze, D. W. Holdsworth, et al., "Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound," Cancer Research, vol. 67, pp. 2830-2839, 2007.
[40] M. Palmowski, J. Huppert, P. Hauff, M. Reinhardt, K. Schreiner, M. A. Socher, et al., "Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment," Cancer Research, vol. 68, pp. 7042-7049, 2008.
[41] R. F. Chang, S. F. Huang, W. K. Moon, Y. H. Lee, and D. R. Chen, "Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification," Radiology, vol. 243, pp. 56-62, 2007.
[42] D. E. Goertz, J. L. Yu, R. S. Kerbel, P. N. Burns, and F. S. Foster, "High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow," Cancer Research, vol. 62, pp. 6371-6375, 2002.
[43] M. Jugold, M. Palmowski, J. Huppert, E. C. Woenne, M. M. Mueller, W. Semmler, et al., "Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice," European Radiology, vol. 18, pp. 753-758, 2008.
[44] D. E. Goertz, J. L. Yu, R. S. Kerbel, P. N. Burns, and F. S. Foster, "High-frequency 3-D color-flow imaging of the microcirculation," Ultrasound in Medicine and Biology, vol. 29, pp. 39-51, 2003.
[45] R. A. Linden, E. J. Trabulsi, F. Forsberg, P. R. Gittens, L. G. Gomella, and E. J. Halpern, "Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies," Journal of Urology, vol. 178, pp. 2354-2358, 2007.
[46] J.-B. Liu, G. Wansaicheong, D. A. Merton, S.-Y. Chiou, Y. Sun, K. Li, et al., "Canine prostate: Contrast-enhanced US-guided radiofrequency ablation with urethral and neurovascular cooling - Initial experience," Radiology, vol. 247, pp. 717-725, 2008.
[47] M. J. Mitterberger, F. Aigner, W. Horninger, H. Ulmer, S. Cavuto, E. J. Halpern, et al., "Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection," European Radiology, vol. 20, pp. 2791-2796, 2010.
[48] N. de Jong, M. Emmer, A. van Wamel, and M. Versluis, "Ultrasonic characterization of ultrasound contrast agents," Medical & Biological Engineering & Computing, vol. 47, pp. 861-873, 2009.
[49] S. Sirsi, J. Feshitan, J. Kwan, S. Homma, and M. Borden, "Effect of microbubble size on fundamental mode high frequency ultrasound imaging in mice," Ultrasound in Medicine and Biology, vol. 36, pp. 935-948, 2010.
[50] D. T. Linker, P. G. Yock, Å. Grønningsæther, E. Johansen, and B. A. Angelsen, "Analysis of backscattered ultrasound from normal and diseased arterial wall," The International Journal of Cardiac Imaging, vol. 4, pp. 177-185, 1989.
[51] D. E. Goertz, D. A. Christopher, J. L. Yu, R. S. Kerbel, P. N. Burns, and F. S. Foster, "High-frequency color flow imaging of the microcirculation," Ultrasound in Medicine and Biology, vol. 26, pp. 63-71, 2000.
[52] C. Liu, F. Djuth, X. Li, R. Chen, Q. Zhou, and K. K. Shung, "Micromachined high frequency PMN-PT/epoxy 1–3 composite ultrasonic annular array," Ultrasonics, vol. 52, pp. 497-502, 2012.
[53] C. Liu, Q. Zhou, F. Djuth, and K. K. Shung, "High-frequency (>50 MHz) medical ultrasound linear arrays fabricated from micromachined bulk PZT materials," Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 59, pp. 315-318, 2012.
[54] F. S. Foster, C. J. Pavlin, K. A. Harasiewicz, D. A. Christopher, and D. H. Turnbull, "Advances in ultrasound biomicroscopy," Ultrasound in Medicine and Biology, vol. 26, pp. 1-27, 2000.
[55] Q. Zhang, H. Yang, S. J. Kang, Y. Wang, G. D. Wang, T. Coulthard, et al., "In vivo figh-frequency, contrast-enhanced ultrasonography of uveal melanoma in mice: imaging features and histopathologic correlations," Investigative Ophthalmology & Visual Science, vol. 52, pp. 2662-2668, 2011.
[56] D. E. Kruse, R. H. Silverman, R. J. Fornaris, D. J. Coleman, and K. W. Ferrara, "A swept-scanning mode for estimation of blood velocity in the microvasculature," Ieee Transactions on Ultrasonics Ferroelectrics and Frequency Control, vol. 45, pp. 1437-1440, 1998.
[57] C. K. Yeh, J. J. Chen, M. L. Li, J. J. Luh, and J. J. J. Chen, "In vivo imaging of blood flow in the mouse Achilles tendon using high-frequency ultrasound," Ultrasonics, vol. 49, pp. 226-230, 2009.
[58] J. J. Chen, J. J. J. Chen, C. S. Chiang, J. H. Hong, and C. K. Yeh, "Assessment of tumor vasculature for diagnostic and therapeutic applications in a mouse model in vivo using 25-MHz power Doppler imaging," Ultrasonics, vol. 51, pp. 925-931, 2011.
[59] J. J. Chen, S. Y. Fu, C. S. Chiang, J. H. Hong, and C. K. Yeh, "Characterization of tumor vasculature distributions in central and peripheral regions based on Doppler ultrasound," Med Phys, vol. 39, pp. 7490-8, 2012.
[60] J. J. Chen, S. Y. Fu, C. S. Chiang, J. H. Hong, and C. K. Yeh, "A preclinical study to explore vasculature differences between primary and recurrent tumors using ultrasound Doppler imaging," Ultrasound Med Biol, vol. 39, pp. 860-9, 2013.
[61] S. F. Huang, R. F. Chang, W. K. Moon, Y. H. Lee, D. R. Chen, and J. S. Suri, "Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images," IEEE Trans Med Imaging, vol. 27, pp. 320-30, 2008.
[62] C. M. Sehgal, P. H. Arger, S. E. Rowling, E. F. Conant, C. Reynolds, and J. A. Patton, "Quantitative vascularity of breast masses by Doppler imaging: Regional variations and diagnostic implications," Journal of Ultrasound in Medicine, vol. 19, pp. 427-440, 2000.
[63] M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, et al., "Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations," Cancer Research, vol. 61, pp. 2974-2982, 2001.
[64] A. K. W. Wood, R. M. Bunte, J. D. Cohen, J. H. Tsai, W. M. F. Lee, and C. M. Sehgal, "The antivascular action of physiotherapy ultrasound on a murine tumor: Role of a microbubble contrast agent," Ultrasound in Medicine and Biology, vol. 33, pp. 1901-1910, 2007.
[65] F. Denis, P. Bougnoux, W. de Poncheville, M. Prat, R. Catroux, and F. O. Tranquart, "In vivo quantitation of tumour vascularisation assessed by Doppler sonography in rat mammary tumours," Ultrasound in Medicine and Biology, vol. 28, pp. 431-437, 2002.
[66] R. L. Birdwell, D. M. Ikeda, S. S. Jeffrey, and R. B. Jeffrey, Jr., "Preliminary experience with power Doppler imaging of solid breast masses," AJR Am J Roentgenol, vol. 169, pp. 703-7, 1997.
[67] K. Palagyi, J. Tschirren, E. A. Hoffman, and M. Sonka, "Quantitative analysis of pulmonary airway tree structures," Comput Biol Med, vol. 36, pp. 974-96, 2006.
[68] Y. F. Tsao and K. S. Fu, "A parallel thinning algorithm for 3-D pictures," Computer Graphics and Image Processing, vol. 17, pp. 315-331, 1981.
[69] J. R. Less, T. C. Skalak, E. M. Sevick, and R. K. Jain, "Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions," Cancer Res, vol. 51, pp. 265-73, 1991.
[70] G. O. Ahn and J. M. Brown, "Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells," Cancer Cell, vol. 13, pp. 193-205, 2008.
[71] P. Vaupel, "Tumor microenvironmental physiology and its implications for radiation oncology," Semin Radiat Oncol, vol. 14, pp. 198-206, 2004.
[72] C. S. Tsai, F. H. Chen, C. C. Wang, H. L. Huang, S. M. Jung, C. J. Wu, et al., "Macrophages from irradiated tumors express higher levels of iNOS, Arginase-I and COX-2, and promote tumor growth," International Journal of Radiation Oncology Biology Physics, vol. 68, pp. 499-507, 2007.
[73] L. Zhao, Y. Zhan, J. L. Rutkowski, G. Z. Feuerstein, and X. Wang, "Correlation between 2- and 3-dimensional assessment of tumor volume and vascular density by ultrasonography in a transgenic mouse model of mammary carcinoma," J Ultrasound Med, vol. 29, pp. 587-95, 2010.
[74] S. D. Tong, H. N. Cardinal, R. F. McLoughlin, D. B. Downey, and A. Fenster, "Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging," Ultrasound in Medicine and Biology, vol. 24, pp. 673-681, 1998.
[75] B. G. Zagar, R. J. Fornaris, and K. W. Ferrara, "Ultrasonic mapping of the microvasculature: Signal alignment," Ultrasound in Medicine and Biology, vol. 24, pp. 809-824, 1998.
[76] C. Kasai, "Real-time two-dimensional blood flow imaging using an autocorrelation technique," Ieee Transactions on Ultrasonics Ferroelectrics and Frequency Control, vol. 33, pp. 94-94, 1986.
[77] C. M. Sehgal, P. H. Arger, A. C. Silver, J. A. Patton, H. M. Saunders, A. Bhattacharyya, et al., "Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: Initial results in a canine study," Radiology, vol. 219, pp. 419-426, 2001.
[78] C. Menon and D. L. Fraker, "Tumor oxygenation status as a prognostic marker," Cancer Letters, vol. 221, pp. 225-235, 2005.
[79] T. Kuwa, B. S. Jordan, and L. C. Cancio, "Use of power Doppler ultrasound to monitor renal perfusion during burn shock," Burns, vol. 32, pp. 706-713, 2006.
[80] C. Menon, G. M. Polin, I. Prabakaran, A. Hsi, C. Cheung, J. P. Culver, et al., "An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model," Cancer Research, vol. 63, pp. 7232-7240, 2003.
[81] H. Bernsen, P. Rijken, T. Oostendorp, and A. J. Vanderkogel, "Vascularity and perfusion of human gliomas xenograft in the athymic nude-mouse " British Journal of Cancer, vol. 71, pp. 721-726, 1995.
[82] J. Bussink, J. H. A. M. Kaanders, P. F. J. W. Rijken, J. P. W. Peters, R. J. Hodgkiss, H. A. M. Marres, et al., "Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts, effects of carbogen and nicotinamide," Radiotherapy and Oncology, vol. 50, pp. 173-184, 1999.
[83] M. E. Eichhorn, A. Kleespies, M. K. Angele, K. W. Jauch, and C. J. Bruns, "Angiogenesis in cancer: molecular mechanisms, clinical impact," Langenbecks Archives of Surgery, vol. 392, pp. 371-379, 2007.
[84] A. C. Fleischer, "Sonographic depiction of tumor vascularity and flow: From in vivo models to clinical applications," Journal of Ultrasound in Medicine, vol. 19, pp. 55-61, 2000.
[85] A. G. Taghian, R. Abi-Raad, S. I. Assaad, A. Casty, M. Ancukiewicz, E. Yeh, et al., "Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications," Journal of Clinical Oncology, vol. 23, pp. 1951-1961, 2005.
[86] J. J. Kim and I. F. Tannock, "Repopulation of cancer cells during therapy: An important cause of treatment failure," Nature Reviews Cancer, vol. 5, pp. 516-525, 2005.
[87] T. Miyamoto, S. Ishii, K. Eguchi-Kasai, and K. Koyama-Saegusa, "Radiosensitivity of hypoxic and proliferating clonogen in a human lung cancer grown in nude mice," Oncology Reports, vol. 14, pp. 1421-1428, 2005.
[88] F. C. Galmarini, C. M. Galmarini, M. I. Sarchi, J. Abulafia, and D. Galmarini, "Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer," Microcirculation, vol. 7, pp. 405-410, 2000.
[89] E. F. Donnelly, L. Geng, W. E. Wojcicki, A. C. Fleischer, and D. E. Hallahan, "Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels," Radiology, vol. 219, pp. 166-170, 2001.
[90] G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken, "Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature," Clinical Cancer Research, vol. 13, pp. 323-330, 2007.
[91] P. N. Lin, S. Sankar, S. Q. Shan, M. W. Dewhirst, P. J. Polverini, T. Q. Quinn, et al., "Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor," Cell Growth & Differentiation, vol. 9, pp. 49-58, 1998.
[92] D. Wang, C. R. Stockard, L. Harkins, P. Lott, C. Salih, K. Yuan, et al., "Immunohistochemistry in the evaluation of neovascularization in tumor xenografts," Biotechnic & Histochemistry, vol. 83, pp. 179-189, 2008.
[93] R. J. Stewart, T. S. Kashour, and P. A. Marsden, "Vascular endothelial platelet endothelial cell adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma - Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells," Journal of Immunology, vol. 156, pp. 1221-1228, 1996.
[94] R. K. Jain, "Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy," Science, vol. 307, pp. 58-62, 2005.
[95] F. H. Chen, C. S. Chiang, C. C. Wang, C. S. Tsai, S. M. Jung, C. C. Lee, et al., "Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors," Clinical Cancer Research, vol. 15, pp. 1721-1729, 2009.
[96] S. Goel, D. G. Duda, L. Xu, L. L. Munn, Y. Boucher, D. Fukumura, et al., "Normalization of the vasculature for treatment of cancer and other diseases," Physiological Reviews, vol. 91, pp. 1071-1121, 2011.
[97] R. K. Jain, "Determinants of tumor blood-flow: a review," Cancer Research, vol. 48, pp. 2641-2658, 1988.
[98] V. M. Lukasik and R. J. Gillies, "Animal anaesthesia for in vivo magnetic resonance," Nmr in Biomedicine, vol. 16, pp. 459-467, 2003.
[99] H. J. J. A. Bernsen, P. F. J. W. Rijken, N. E. M. Hagemeier, and A. J. van der Kogel, "A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites," Microvascular Research, vol. 57, pp. 244-257, 1999.
[100] H. W. Guo, H. T. He, and M. Chen, "Gamma correction for digital fringe projection profilometry," Applied Optics, vol. 43, pp. 2906-2914, 2004.
[101] M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, et al., "Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T," Molecular Cancer Therapeutics, vol. 5, pp. 1950-1957, 2006.
[102] S. Ohlerth, M. Wergin, C. R. Bley, F. Del Chicca, D. Laluhova, B. Hauser, et al., "Correlation of quantified contrast-enhanced power Doppler ultrasonography with immunofluorescent analysis of microvessel density in spontaneous canine tumours," Veterinary Journal, vol. 183, pp. 58-62, 2010.
[103] T. W. Grunt, A. Lametschwandtner, K. Karrer, and O. Staindl, "The angioarchitecture of the lewis lung-carcinoma in laboratory mice (a light microscopic and scanning electron-microscopic study)," Scanning Electron Microscopy, pp. 557-573, 1986.
[104] O. Kisker, C. M. Becker, D. Prox, M. Fannon, R. D'Amato, E. Flynn, et al., "Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model," Cancer Research, vol. 61, pp. 7669-7674, 2001.
[105] R. S. Kerbel and B. A. Kamen, "The anti-angiogenic basis of metronomic chemotherapy," Nature Reviews Cancer, vol. 4, pp. 423-436, 2004.
[106] S. L. Scott, P. H. Gumerlock, L. Beckett, Y. J. Li, and Z. Goldberg, "Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation," International Journal of Radiation Oncology Biology Physics, vol. 59, pp. 219-227, 2004.
[107] C. M. Mach, L. Mathew, S. A. Mosley, R. Kurzrock, and J. A. Smith, "Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model," Anticancer Research, vol. 29, pp. 1895-1899, 2009.
[108] F. Shojaei, "Anti-angiogenesis therapy in cancer: current challenges and future perspectives," Cancer Lett, vol. 320, pp. 130-7, 2012.